PMID: 41765029

Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.

Rosenstock Julio, Yabe Daisuke, Cox David, Li Jianghao, Denning Max, Wu Wen-Shuo, Liu Rong, Zhao Youna, ACHIEVE-3 Investigators

Lancet (London, England) · 2026

Vol. 407, Issue 10534, pp. 1147-1160

View on PubMedDOI

This entry links to third-party literature. For research use only.

AdultAgedFemaleHumansMaleMiddle AgedAdministration, OralDiabetes Mellitus, Type 2Drug Administration ScheduleGlycated Hemoglobin

For research use only. This index links to third-party literature. Nothing here constitutes medical advice.